X4 Pharmaceuticals, Inc. (XFOR:NASDAQ) closed at $3.20 on October 22, 2026, up 6.31% on the day. The stock trades 33.7% below its 52-week high of $4.83 and 31.7% above its 52-week low of $2.43. Over the past year, it gained 3.6%. X4 Pharmaceuticals, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 22, 2025, XFOR closed higher on 116 days (46%). Its best day was October 24, 2025 (+22.98%) and its worst was December 1, 2025 (-13.46%). The stock moved 10% or more in a single session 14 times. It opened at least 5% above the previous day's high 1 time.
Arsanis Inc discovers and develops monoclonal antibodies for the targeted immunotherapy of serious infections. The company's monoclonal antibodies selectively focus on specific pathogens and pathogenic processes which address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. Few of its products candidates are ASN100, for prevention of pneumonia in high risk, mechanically ventilated patients; ASN500, for prevention of respiratory Syncytial virus; ASN300 and ASN200, for prevention and treatment of bacterial infections.
Find more stocks like XFOR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.